[Chemotherapy at the end-of-life: the reasons why it is not a good parameter for evaluating clinical choices in oncology].

Anticancer treatments at the end of life are considered inappropriate and are used as a quality indicator of clinical behaviours in oncology. However, given the changing of disease trajectories and the availability of new, active treatments, it can n…

Preview only. Read the full abstract at the source